Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy-Reference-Cited by-同舟云学术

Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy

Published:2019-09-03 Issue:9 Volume:14 Page:e0221097
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Muntoni Francesco^ORCID,Domingos Joana,Manzur Adnan Y.,Mayhew Anna,Guglieri Michela,Sajeev Gautam,Signorovitch James,Ward Susan J.,

Funder

Biomarin

Pfizer

PTC Therapeutics

Sarepta

Shire (now Takeda)

Collaborative Trajectory Analysis Project

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference62 articles.

1. Dystrophin: the protein product of the Duchenne muscular dystrophy locus;EP Hoffman;Cell,1987

2. A Systematic Review and Meta-analysis on the Epidemiology of the Muscular Dystrophies;JK Mah;Can J Neurol Sci,2016

3. Clinical features and classification of the muscular dystrophies;D. Gardner-Medwin;Br Med Bull,1980

4. National Institute of Neurological Disorders and Stroke (NINDS). Muscular Dystrophy Information 2017 [February 8, 2017]. Available from: https://www.ninds.nih.gov/Disorders/All-Disorders/Muscular-Dystrophy-Information-Page.

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early motor, cognitive, language, behavioural and social emotional development in infants and young boys with Duchenne Muscular Dystrophy- A systematic review;European Journal of Paediatric Neurology;2024-09

2. Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA;Neuromuscular Disorders;2024-08

3. Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module;Neuromuscular Disorders;2024-08

4. The use of the drug ataluren for the treatment of patients with Duchenne muscular dystrophy in real clinical practice;L.O. Badalyan Neurological Journal;2024-07-31

5. Current Challenges of Using Patient-Level Claims and Electronic Health Record Data for the Longitudinal Evaluation of Duchenne Muscular Dystrophy Outcomes;Advances in Therapy;2024-07-30